• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by TransCode Therapeutics Inc.

    8/14/25 9:55:30 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNAZ alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    TRANSCODE THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    89357L402

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    89357L402


    1Names of Reporting Persons

    Anson Funds Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    27,125.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    27,125.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    27,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    89357L402


    1Names of Reporting Persons

    Anson Management GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    27,125.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    27,125.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    27,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    89357L402


    1Names of Reporting Persons

    Tony Moore
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    27,125.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    27,125.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    27,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    89357L402


    1Names of Reporting Persons

    Anson Advisors Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    27,125.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    27,125.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    27,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    FI, CO


    SCHEDULE 13G

    CUSIP No.
    89357L402


    1Names of Reporting Persons

    Amin Nathoo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    27,125.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    27,125.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    27,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    89357L402


    1Names of Reporting Persons

    Moez Kassam
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    27,125.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    27,125.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    27,125.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TRANSCODE THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    6 Liberty Square, #2382, Boston, MASSACHUSETTS , 02109.
    Item 2. 
    (a)Name of person filing:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam
    (b)Address or principal business office or, if none, residence:

    For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore: 16000 Dallas Parkway, Suite 800 Dallas, Texas 75248 For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam: 181 Bay Street, Suite 4200 Toronto, ON M5J 2T3
    (c)Citizenship:

    Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    89357L402
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Canadian Investment Advisor
    Item 4.Ownership
    (a)Amount beneficially owned:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 27,125 shares of Common Stock held by the Fund.
    (b)Percent of class:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 0.1% of the outstanding shares of Common Stock, which includes shares of Common Stock underlying outstanding warrants (each, a "Warrant," and collectively, the "Warrants") held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam. This percentage is determined by dividing 27,125 by 23,368,461, which is the sum of: (i) 23,341,336 shares of Subordinate Voting Shares issued and outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 12, 2025; and (ii) 27,125 the number of shares of Common Stock receivable by the Fund upon exercise of the Warrants.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Section 4(a)

     (ii) Shared power to vote or to direct the vote:

    See Section 4(a)

     (iii) Sole power to dispose or to direct the disposition of:

    See Section 4(a)

     (iv) Shared power to dispose or to direct the disposition of:

    See Section 4(a)

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Anson Advisors Inc. is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Anson Funds Management LP
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Anson Management GP LLC
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Tony Moore
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Anson Advisors Inc.
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo, Director
    Date:08/14/2025
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam, Director
    Date:08/14/2025
     
    Amin Nathoo
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo, Director
    Date:08/14/2025
     
    Moez Kassam
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam, Director
    Date:08/14/2025
    Get the next $RNAZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNAZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RNAZ
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by TransCode Therapeutics Inc.

    SCHEDULE 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

    8/14/25 9:55:30 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by TransCode Therapeutics Inc.

    10-Q - Transcode Therapeutics, Inc. (0001829635) (Filer)

    8/14/25 4:15:45 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by TransCode Therapeutics Inc.

    SCHEDULE 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

    8/14/25 2:16:01 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Marquet Magda

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    6/18/24 4:16:51 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Manting Erik

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    6/18/24 4:16:30 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Interim CEO, CFO Fitzgerald Thomas A

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    6/18/24 4:15:52 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

    RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drugBOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including  Nobel Laureate, Dr Phillip

    5/28/25 8:00:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

    15 patients treated across four escalating dose levels of TTX-MC138No significant safety or dose limiting toxicities reported10 patients remain on study with no evidence of disease progressionPD analysis at 24 hours post-dosing provides evidence of miR-10b target engagementBOSTON, May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Commi

    5/8/25 8:05:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

    BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split. TransCode's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on May 15, 2025, under the current trading symbol, "RNAZ." The reverse stock split was approved by TransCode's stockholders and Board of Directors on May 2, 2025, and is intended to increase the per share trading price of

    5/5/25 5:07:00 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fitzgerald Thomas A bought $25,168 worth of shares (49,350 units at $0.51), increasing direct ownership by 708% to 56,318 units (SEC Form 4)

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    10/2/23 4:39:08 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dudley Robert Michael bought $49,980 worth of shares (98,000 units at $0.51), increasing direct ownership by 119% to 180,262 units (SEC Form 4)

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    10/2/23 4:37:49 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Financials

    Live finance-specific insights

    View All

    TransCode Therapeutics Acquires Option for Radiotheranostic Technology

    BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.

    5/19/22 9:00:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

    RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drugBOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including  Nobel Laureate, Dr Phillip

    5/28/25 8:00:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

    BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios.  He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approv

    3/28/24 8:30:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update

    BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2022, and recent business progress. "We continued to advance our therapeutic programs during the third quarter," said Michael Dudley, co-founder, president and CEO of TransCode. "We remain on track to achieve our planned milestones for 2H of 2022 which include submission of an exploratory Investigational New Drug Application (eIND) this year for our planned Phase 0 clinical trial in up to 12 cancer patients with advanced solid tumors. We

    11/14/22 4:15:00 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TransCode Therapeutics Inc.

    SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

    11/6/24 4:05:33 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TransCode Therapeutics Inc.

    SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

    7/26/24 4:05:13 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by TransCode Therapeutics Inc.

    SC 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)

    6/21/24 4:02:06 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care